Loading…
Funding will support Phase 3 trial and NDA resubmission for schizophrenia treatment.
Minerva Neurosciences, Inc. (Nasdaq: NERV) announced on October 21, 2025, that it has secured up to $200 million in financing to advance its drug Roluperidone for the treatment of negative symptoms in patients with schizophrenia. The financing includes an initial $80 million, with an additional $40 million contingent on certain milestones, and up to an additional $80 million based on future performance indicators.
The funds will be utilized to conduct a Phase 3 confirmatory trial and support the resubmission of Minerva's New Drug Application (NDA) for Roluperidone. The agreement also allows for up to three additional directors to join Minerva's board.
As of the latest data, Minerva Neurosciences has a free float of 5,437,000 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.